Aviva backs $1.25 billion life sciences hub in London

1 May 2025

UK investment firm Aviva Capital Partners is supporting a major new life sciences expansion in south London, which aims to transform Sutton’s London Cancer Hub into one of the world’s leading centers for oncology research and treatment.

The proposal outlines plans for around one million square feet of advanced lab and research space to be developed next to The Institute of Cancer Research and The Royal Marsden’s Sutton campus. The £1 billion ($1.25 billion) investment aims to house life sciences giants, biotech start-ups, and academic partners under one roof to accelerate cancer innovation.

Expected to be reviewed by the local council in 2025, the plan follows consultation with the community and will feature a ‘Learning Lab’ to inspire young people to pursue science and technology careers.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK